Biblio Discovery — Demo Discovery Service

11 results for "John Powderly"

Showing 1–11 · 0.80 seconds · RSS

  1. Journal Article

    First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

    Toshio Shimizu; John Powderly; Albiruni Abdul Razak et al.

    Frontiers in Oncology, Vol. 14 · 2024 · English · DOAJ Scopus

    BackgroundTransforming growth factor (TGF)-ß1 is a pleiotropic cytokine that can promote tumor growth and suppress antitumor immune responses. Latent TGF-ß1 associates with glycoprotein-A repetition predominant (GARP) on the surface of regulatory T cells prior to its activation and release…

  2. Journal Article

    Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

    Ying Zhu; Tao Huang; John Powderly et al.

    Journal for ImmunoTherapy of Cancer, Vol. 12 No. 11 · 2024 · English · DOAJ Scopus

    Purpose In this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), was investigated in patients with advanced solid tumors as monotherapy and in combination with pembrolizumab, an…

  3. Journal Article

    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

    John Powderly; Alexander Spira; Shunsuke Kondo et al.

    Clinical and Translational Science, Vol. 14 No. 1 · 2021 · English · DOAJ Scopus

    Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigalimab dose selection from monotherapy dose escalation…